Clinical Trial Update: JSP191 Antibody Targeting Conditioning in SCID Patients [Phase 1, Phase 2]

View source ↗

Summary

Jasper Therapeutics' JSP-191 (anti-CD117 antibody) used as conditioning for hematopoietic stem cell transplantation in severe combined immunodeficiency (SCID) p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Combined Immunodeficiency

Drugs mentioned

• JSP-191 (anti-CD117 monoclonal antibody)

Snippet

Sponsor: Jasper Therapeutics, Inc. | Conditions: SCID | Phase 1, Phase 2 | Status: TERMINATED